Navigation Links
NanoBio Corporation Raises $12 Million in Series B Financing
Date:2/18/2009

ANN ARBOR, Mich., Feb. 18 /PRNewswire/ -- NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing with Perseus LLC and other existing investors. To date, over $80 million in funding has been directed toward the development of the company's NanoStat(TM) technology platform.

The series B funding will be used by the company to complete a phase 1 study investigating a novel topical treatment for acne, preclinical studies on a nebulized therapy for cystic fibrosis, and a phase 1 study for an intranasal seasonal influenza vaccine.

This funding follows several recent product announcements by NanoBio, including:

-- Phase 2b data indicating that the company's topical herpes labialis product speeds healing as effectively as the leading oral systemic drugs but without safety or toxicity concerns

-- Preclinical data demonstrating that the company's novel nanoemulsion technology kills highly resistant bacteria found in patients with cystic fibrosis

-- Preclinical data indicating that a single administration of NanoBio's novel intranasal influenza vaccine elicits immune responses in ferrets more than 20 times higher than those generated by two injections of currently approved vaccines

"We are pleased with the continued, strong support of Perseus and the company's other investors," said James R. Baker Jr., M.D., founder and chairman of NanoBio Corp. "Based upon the strength of our recent data and our future development plans, there was significant interest from investors with respect to participating in this financing despite the challenging economic conditions."

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.


'/>"/>
SOURCE NanoBio Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
2. NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
3. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
4. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
5. David M. Stout Joins NanoBio Corporations Board of Directors
6. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
7. NanoBio Expands Drug Development Team for Its Anti-Infective Products
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
9. Newbridge Securities Corporation Forms BioVentures Division
10. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
11. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u ... Cooking Challenge is a two-hour team-building package designed for groups of 10-30 people. ... Jodi Abel, which include items, such as Blackened Shrimp with Edamame Salad, Pizza ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... NDA Partners ... executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business ... to his position at Eurofins and Cardinal Health, he was former Chief Operating Officer ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition Corporation ... commercialization, has just released version 9.0 of the Cognition Cockpit platform. , “Our ... Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled to finally be able ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... equipment for varying industries, including food and dairy, munitions, and pharmaceutical/biotech, recently introduced ... safety and ease of use. The improvement in technology comes on the heels ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):